The Deepbridge Life Sciences EIS team prepares and reviews investment opportunities sourced from a wide dealflow network. Generally, Deepbridge seeks investment opportunities that exhibit the following qualities:
- A focus on life sciences and medical device technology;
- Significant market potential with clear need and market growth;
- Provide a solution to a recognised clinical or healthcare need;
- Innovation-driven products that have the potential to create new market segments or displace current technologies;
- Medical technology businesses with a clear and realistic path to commercialisation;
- Robust intellectual property which may provide patented or patentable IP protection
- Passionate, energetic, experienced and aligned founding team;
- Clear exit strategy to be implemented within 4-5 years with alignment of interests with our stakeholders.
Deepbridge will take an active executive role on the Board of the investee companies to utilise the strengths and commercial experience that the Deepbridge team possess in order to accelerate the growth of the investee company.
For more information on the Deepbridge Life Sciences EIS, please click here.
Dr Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital.
- November 2019 (6)
- October 2019 (7)
- September 2019 (7)
- August 2019 (5)
- July 2019 (4)
- June 2019 (1)
- May 2019 (5)
- April 2019 (6)
- March 2019 (4)
- February 2019 (4)
- January 2019 (5)
- December 2018 (1)
- November 2018 (1)
- October 2018 (4)
- September 2018 (7)
- August 2018 (2)
- July 2018 (2)
- June 2018 (2)